DE COBELLI, OTTAVIO
 Distribuzione geografica
Continente #
EU - Europa 27.150
AS - Asia 19.663
NA - Nord America 17.968
SA - Sud America 1.871
AF - Africa 448
OC - Oceania 130
Continente sconosciuto - Info sul continente non disponibili 13
Totale 67.243
Nazione #
US - Stati Uniti d'America 17.264
DE - Germania 12.696
SG - Singapore 5.732
CN - Cina 5.517
IT - Italia 4.283
GB - Regno Unito 3.472
BD - Bangladesh 2.447
HK - Hong Kong 1.808
RU - Federazione Russa 1.577
SE - Svezia 1.524
BR - Brasile 1.393
VN - Vietnam 1.340
FR - Francia 969
IN - India 903
IE - Irlanda 553
NL - Olanda 511
CA - Canada 421
FI - Finlandia 382
TR - Turchia 361
KR - Corea 331
ID - Indonesia 287
JP - Giappone 260
UA - Ucraina 242
CI - Costa d'Avorio 179
DK - Danimarca 156
AR - Argentina 145
ES - Italia 129
MX - Messico 127
AU - Australia 119
AT - Austria 113
PH - Filippine 110
PL - Polonia 105
EU - Europa 91
IQ - Iraq 88
CO - Colombia 78
BE - Belgio 76
ZA - Sudafrica 70
EC - Ecuador 68
GR - Grecia 65
PK - Pakistan 60
CH - Svizzera 56
CL - Cile 51
MA - Marocco 49
PE - Perù 42
VE - Venezuela 38
EG - Egitto 36
SA - Arabia Saudita 35
UZ - Uzbekistan 34
MY - Malesia 33
PT - Portogallo 32
AE - Emirati Arabi Uniti 31
TH - Thailandia 29
IR - Iran 28
JO - Giordania 28
KE - Kenya 28
TW - Taiwan 28
NO - Norvegia 27
RO - Romania 27
CR - Costa Rica 25
CZ - Repubblica Ceca 23
JM - Giamaica 23
PY - Paraguay 23
AZ - Azerbaigian 22
NP - Nepal 22
TT - Trinidad e Tobago 22
IL - Israele 21
UY - Uruguay 21
TN - Tunisia 20
KZ - Kazakistan 18
LT - Lituania 17
NG - Nigeria 15
EE - Estonia 14
AL - Albania 13
ET - Etiopia 13
GT - Guatemala 12
HN - Honduras 12
BO - Bolivia 11
DO - Repubblica Dominicana 10
LU - Lussemburgo 10
OM - Oman 10
PS - Palestinian Territory 10
BY - Bielorussia 9
HU - Ungheria 9
KG - Kirghizistan 9
LB - Libano 9
RS - Serbia 9
SK - Slovacchia (Repubblica Slovacca) 9
BG - Bulgaria 8
HR - Croazia 8
MK - Macedonia 8
NI - Nicaragua 8
NZ - Nuova Zelanda 8
PA - Panama 8
AM - Armenia 7
SC - Seychelles 7
BH - Bahrain 6
CU - Cuba 6
GE - Georgia 6
BB - Barbados 5
SV - El Salvador 5
Totale 67.215
Città #
Frankfurt am Main 11.672
Singapore 3.058
Southend 2.991
Ashburn 2.293
Hong Kong 1.534
San Jose 1.271
Chandler 1.168
Milan 1.117
Dallas 1.013
Beijing 984
Santa Clara 698
Council Bluffs 661
Seattle 654
Los Angeles 592
Hefei 575
Princeton 572
Dublin 549
New York 508
Fairfield 468
Wilmington 452
Ho Chi Minh City 390
Buffalo 388
Lauterbourg 360
Bengaluru 351
Houston 342
Hanoi 320
Rome 297
Moscow 273
Guangzhou 240
Ann Arbor 218
Woodbridge 211
Des Moines 210
Nanjing 208
Boardman 197
Jakarta 195
Cambridge 190
Abidjan 179
Dearborn 172
Mountain View 172
Shanghai 167
Munich 165
Tokyo 160
Naples 157
Columbus 156
Helsinki 152
Redmond 145
São Paulo 140
Phoenix 136
Berlin 126
Cangzhou 121
Seoul 115
Jinan 114
The Dalles 113
Toronto 113
Turin 111
Tianjin 107
Jacksonville 104
Istanbul 100
Chicago 99
Changsha 93
Shenyang 93
Montreal 83
London 81
Nuremberg 74
Sakarya 74
Bologna 71
Hyderabad 68
Redwood City 64
Shenzhen 63
Brussels 61
Orem 60
Washington 60
Haiphong 58
Athens 57
Eitensheim 56
Florence 56
Nanchang 56
Bari 55
Hebei 55
Turku 55
Mumbai 54
Warsaw 54
Atlanta 53
Hangzhou 53
Grafing 52
San Diego 52
Vienna 52
Somerville 49
Zhengzhou 49
Da Nang 48
Bogotá 46
Fuzhou 46
Palermo 46
Amsterdam 44
Ottawa 44
Rio de Janeiro 44
Silver Spring 43
Andover 42
Dong Ket 42
Brooklyn 40
Totale 42.690
Nome #
Perioperative outcomes of robotic and laparoscopic simple prostatectomy: a European-American multi-institutional analysis 658
Overview of potential determinants of radical prostatectomy versus radiation therapy in management of clinically localized prostate cancer: results from an Italian, prospective, observational study (the Pros-IT CNR study) 585
A novel nomogram to identify candidates for active surveillance among patients with ISUP Grade Group 1 or ISUP Grade Group 2 prostate cancer, according to multiparametric magnetic resonance imaging findings 483
Low PI-RADS assessment category excludes extraprostatic extension (≥pT3a) of prostate cancer : a histology-validated study including 301 operated patients 429
Radioablation +/- hormonotherapy for prostate cancer oligorecurrences (Radiosa trial): Potential of imaging and biology (AIRC IG-22159) 422
Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: The Pros-IT CNR study 403
Reirradiation for isolated local recurrence of prostate cancer: Mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT) 376
Whole-body magnetic resonance imaging (WB-MRI) reporting with the METastasis Reporting and Data System for Prostate Cancer (MET-RADS-P) : inter-observer agreement between readers of different expertise levels 372
Advanced Age Impacts Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma 364
Predicting trajectories of recovery in prostate cancer patients undergone Robot-Assisted Radical Prostatectomy (RARP) 360
Repeated MRIs during Active Surveillance: natural history of prostatic lesions and upgrading rates 359
Accuracy of the European Association of Urology (EAU) NMIBC 2021 scoring model in predicting progression in a large cohort of HG T1 NMIBC patients treated with BCG 346
Prostatectomia radicale robotica in presenza di un voluminoso lobo medio 340
Protocol of the Italian Radical Cystectomy Registry (RIC): a non-randomized, 24-month, multicenter study comparing robotic-assisted, laparoscopic, and open surgery for radical cystectomy in bladder cancer 333
Multiparametric magnetic resonance imaging and frozen-section analysis efficiently predict upgrading, upstaging, and extraprostatic extension in patients undergoing nerve-sparing robotic-assisted radical prostatectomy 325
No increase in toxicity of pelvic irradiation when intensity modulation is employed: clinical and dosimetric data of 208 patients treated with post-prostatectomy radiotherapy 322
Salvage image-guided intensity modulated or stereotactic body reirradiation of local recurrence of prostate cancer 314
Phase II prospective trial “Give Me Five” short-term high precision radiotherapy for early prostate cancer with simultaneous boost to the dominant intraprostatic lesion : the impact of toxicity on quality of life (AIRC IG-13218) 311
The impact of treatment modality on survival in patients with clinical node-positive bladder cancer: results from a multicenter collaboration 310
Mixed-Beam Approach for High-Risk Prostate Cancer Carbon-Ion Boost Followed by Photon Intensity-Modulated Radiotherapy: Preliminary Results of Phase II Trial AIRC-IG-14300 308
Contemporary rates and predictors of open conversion during minimally invasive radical prostatectomy for non-metastatic prostate cancer 306
Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml 304
Long non-coding RNA containing ultraconserved genomic region 8 promotes bladder cancer tumorigenesis 304
CyberKnife Ultra-Hypofractionated SBRT for Localized Prostate Cancer with Dose Escalation to the Dominant Intraprostatic Lesion: In Silico Planning Study 302
[11C]Choline PET/CT impacts treatment decision making in patients with prostate cancer referred for radiotherapy 300
MRI-based radiomics signature for localized prostate cancer: a new clinical tool for cancer aggressiveness prediction? Sub-study of prospective phase II trial on ultra-hypofractionated radiotherapy (AIRC IG-13218) 300
Increased Body Mass Index Is a Risk Factor for Poor Clinical Outcomes after Radical Prostatectomy in Men with International Society of Urological Pathology Grade Group 1 Prostate Cancer Diagnosed with Systematic Biopsies 300
Oligorecurrent Prostate Cancer and Stereotactic Body Radiotherapy: Where Are We Now? A Systematic Review and Meta-analysis of Prospective Studies 299
High-performance prediction models for prostate cancer radiomics 298
Multiparametric Magnetic Resonance Imaging Second Opinion May Reduce the Number of Unnecessary Prostate Biopsies : Time to Improve Radiologists’ Training Program? 295
Evoluzione della tecnica di ricostruzione posteriore dello sfintere striato dopo prostatectomia radicale robotica 290
"Give me five" ultra-hypofractionated radiotherapy for localized prostate cancer: non-invasive ablative approach 290
Cisplatin, etoposide and continuous infusion bleomycin in patients with testicular germ cell tumors: efficacy and toxicity data from a retrospective study 279
Robot-assisted simple prostatectomy (RASP) : does it make sense? 276
Metabolic syndrome predicts worse perioperative outcomes in patients treated with partial nephrectomy for renal cell carcinoma 274
Reporting combined outcomes with Trifecta and survival, continence, and potency (SCP) classification in 337 patients with prostate cancer treated with image-guided hypofractionated radiotherapy 273
Long-term follow‐up outcomes after percutaneous us/ct‐guided radiofrequency ablation for ct1a‐b renal masses : Experience from single high‐volume referral center 270
Robot-assisted radical prostatectomy : multiparametric MR imaging-directed intraoperative frozen-section analysis to reduce the rate of positive surgical margins 270
Correction: Confirmatory multiparametric magnetic resonance imaging at recruitment confers prolonged stay in active surveillance and decreases the rate of upgrading at follow-up (Prostate Cancer and Prostatic Diseases, (2020), 23, 1, (94-101), 10.1038/s41391-019-0160-3) 268
Late toxicity of image-guided hypofractionated radiotherapy for prostate : non-randomized comparison with conventional fractionation 267
A comprehensive evaluation of sexual and reproductive outcomes following robot-assisted retroperitoneal lymph node dissection for nonseminomatous germ cell tumor 265
A novel nomogram predicting lymph node invasion among patients with prostate cancer: The importance of extracapsular extension at multiparametric magnetic resonance imaging 265
A novel "intuitive" surgical technique for right robot-assisted retroperitoneal lymph node dissection for stage I testicular NSGCT 261
Short-term high precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion : ad interim analysis and preliminary results of Phase II trial AIRC-IG-13218 261
Anterior prostatic tumours are difficult to diagnose without MRI 258
Chronic bacterial prostatitis : efficacy of short-lasting antibiotic therapy with prulifloxacin (Unidrox®) in association with saw palmetto extract, lactobacillus sporogens and arbutin (Lactorepens®) 257
Exploring mirna signature and other potential biomarkers for oligometastatic prostate cancer characterization: The biological challenge behind clinical practice : a narrative review 257
Therapeutic Sequences in the Treatment of High-Risk Prostate Cancer: Paving the Way Towards Multimodal Tailored Approaches 257
Confirmatory multiparametric magnetic resonance imaging at recruitment confers prolonged stay in active surveillance and decreases the rate of upgrading at follow-up 251
Pathological findings at radical prostatectomy of biopsy naïve men diagnosed with MRI targeted biopsy alone without concomitant standard systematic sampling 251
Robot assisted radical prostatectomy in kidney transplant recipients: surgical, oncological and functional outcomes of two different robotic approaches 250
Neutrophil, platelets, and eosinophil to lymphocyte ratios predict gleason score upgrading in low-risk prostate cancer patients 250
Validation of the 2009 TNM Version in a large multi-institutional cohort of patients treated for renal cell carcinoma : are further improvements needed? 249
Correlation between radiological and biological features and clinical outcomes in early prostate cancer: an exploratory subgroup analysis 245
Adjuvant radiotherapy in node positive prostate cancer patients: a debate still on. when, for whom? 244
Bladder preservation in non-metastatic muscle-invasive bladder cancer (MIBC): a single-institution experience 241
A global Unified Dosimetry Index (gUDI) to evaluate simultaneous integrated boost radiotherapy plans in prostate cancer 241
Quality of life and psycho-emotional wellbeing in bladder cancer patients and their caregivers: A comparative analysis between urostomy versus ileal orthotopic neobladder 240
Robot-assisted intracorporeal orthotopic ileal neobladder : Description of the “shell” technique 240
Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol 239
Robotic vs open prostatectomy in a laparoscopically naive centre: a matched-pair analysis 238
Cytoreductive prostate radiotherapy in oligometastatic prostate cancer: A single centre analysis of toxicity and clinical outcome 237
Impact of Surgical Approach on Patient-Reported Outcomes after Radical Prostatectomy: A Propensity Score-Weighted Analysis from a Multicenter, Prospective, Observational Study (The Pros-IT CNR Study) 236
Body mass index was associated with upstaging and upgrading in patients with low-risk prostate cancer who met the inclusion criteria for active surveillance 235
Quality assurance for automatically generated contours with additional deep learning 234
Surgical blood loss during holmium laser enucleation of the prostate (HoLEP) is not affected by short-term pretreatment with dutasteride: A double-blind placebo-controlled trial on prostate vascularity 234
Penile-Sparing Surgery for Tumour Recurrence after Previous Glansectomy/Partial Penectomy: Treatment Feasibility and Oncological Outcomes 233
Impact of surgical approach and resection technique on the risk of Trifecta Failure after partial nephrectomy for highly complex renal masses 233
Systemic combining inflammatory score (SCIS): a new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer 233
Dosimetric Evaluation of the Inter-Fraction Motion of Organs at Risk in SBRT for Nodal Oligometastatic Prostate Cancer 233
Urinary bladder preservation for muscle-invasive bladder cancer: a survey among radiation oncologists of Lombardy, Italy 233
Predictors of residual T1 high grade on re-transurethral resection in a large multi-institutional cohort of patients with primary T1 high-grade/grade 3 bladder cancer 233
Mixed-beam approach for high-risk prostate cancer : Carbon-ion boost followed by photon intensity-modulated radiotherapy. Dosimetric and geometric evaluations (AIRC IG-14300) 232
External validation of EORTC risk scores to predict recurrence after transurethral resection of brazilian patients with non -muscle invasive bladder cancer stages Ta and T1 231
Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer 228
Radiotherapy in prostate cancer patients with pelvic lymphocele after surgery: clinical and dosimetric data of 30 patients 228
Predicting Peri-Operative Outcomes in Patients Treated with Percutaneous Thermal Ablation for Small Renal Masses: The SuNS Nephrometry Score 227
An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer 227
Apparent Diffusion Coefficient and Other Preoperative Magnetic Resonance Imaging Features for the Prediction of Positive Surgical Margins in Prostate Cancer Patients Undergoing Radical Prostatectomy 227
Clinical evaluation and disease management of PI-RADS 3 lesions. Analysis from a single tertiary high-volume center 225
ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial 224
How Can the COVID-19 Pandemic Lead to Positive Changes in Urology Residency? 223
Sensitivity and detection rate of a 12-core trans-perineal prostate biopsy : preliminary report 222
Effetto della curva di apprendimento di un Gruppo Laparoscopic Naive sui risultati oncologici e funzionali della prostatectomia radicale robot assisted 222
Acute toxicity of image-guided hypofractionated radiotherapy for prostate cancer: nonrandomized comparison with conventional fractionation 221
Artificial intelligence and radiomics in evaluation of kidney lesions: a comprehensive literature review 220
Stereotactic body radiotherapy for castration-sensitive prostate cancer bone oligometastases 220
Impact of uni- or multifocal perineural invasion in prostate cancer at radical prostatectomy 220
Improving the prediction of pathologic outcomes in patients undergoing radical prostatectomy : the value of prostate cancer antigen 3 (PCA3), prostate health index (Phi) and sarcosine 219
Thulium–yttrium–aluminium–garnet (Tm:YAG) laser treatment of penile cancer: oncological results, functional outcomes, and quality of life 218
Adherence to Guidelines among Italian Urologists on Imaging Preoperative Staging of Low-Risk Prostate Cancer : Results from the MIRROR (Multicenter Italian Report on Radical Prostatectomy Outcomes and Research) Study 215
Beyond PSA : The role of prostate health index (phi) 214
MRI-targeted or systematic random biopsies for prostate cancer diagnosis in biopsy naïve patients: follow-up of a PRECISION trial-like retrospective cohort 214
Finding safe dose-volume constraints for re-irradiation with SBRT of patients with prostate cancer relapse: The IEO experience 214
Outcomes of Partial and Radical Nephrectomy in Octogenarians – A Multicenter International Study (Resurge) 213
"Burned out" phenomenon of the testis in retroperitoneal seminoma 212
Robot-assisted Resection of a Wide-extending Abdominoperineal Angiomyofibroblastoma in a Male Patient 211
Artificial Intelligence in the Advanced Diagnosis of Bladder Cancer-Comprehensive Literature Review and Future Advancement 210
Ultrahypofractionated radiotherapy for localized prostate cancer with simultaneous boost to the dominant intraprostatic lesion : a plan comparison 210
First Live-Experience Session with PET/CT Specimen Imager: A pilot analysis in Prostate Cancer and Neuroendocrine Tumor 209
Totale 27.475
Categoria #
all - tutte 176.883
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 176.883


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.475 197 190 129 171 329 307 220 245 282 295 261 849
2022/20234.738 642 453 417 448 417 816 248 307 527 64 296 103
2023/202410.707 160 239 174 197 728 397 1.712 1.523 740 1.452 1.678 1.707
2024/202512.971 1.572 1.592 1.308 1.149 676 602 459 996 515 860 1.037 2.205
2025/202624.720 2.276 1.800 2.502 1.897 1.830 1.285 2.519 1.080 2.128 1.507 3.233 2.663
2026/2027934 934 0 0 0 0 0 0 0 0 0 0 0
Totale 69.654